摘要
目的探讨小剂量阿立哌唑作为增效剂治疗强迫症的疗效与不良反应。方法将99例强迫症患者按随机数字表法分为3组:A组33例口服盐酸帕罗西汀40 mg·d-1,B组32例口服盐酸帕罗西汀40 mg·d-1+阿立哌唑2.5 mg·d-1,C组34例口服盐酸帕罗西汀40 mg·d-1+阿立哌唑5 mg·d-1。采用耶鲁布朗强迫量表(Y-BOCS)评定3组临床疗效,并采用副反应评定量表(TESS)对3组治疗期间的不良反应情况进行评价。结果治愈率A、B、C组分别为15.1%、28.1%、29.4%,总有效率A、B、C组分别为65.4%、68.7%、64.7%,B、C组治愈率、总有效率均显著高于A组(P<0.05);治疗期间3组不良反应发生率比较差异均无统计学意义(P>0.05)。结论小剂量阿立哌唑作为增效剂治疗强迫症具有明显的增效作用,且无严重不良反应发生。
Objective To investigate the efficacy and adverse reactions of low-dose aripiprazole as synergistic agent in the treatment of obsessive compulsive disorder. Methods Ninety-nine patients with obsessive compulsive disorder were randomly treated with oral paroxetine hydrochloride 40 rag＂ d-1 alone （group A,n=33） or in combination with aripiprazole 2.5 mg·d-1（group B,n=32）or 5 mg·d-1（group C, n=34）. Clinical efficacy and adverse reactions were assessed using Yale-Brown Obsessive Compulsive Scale （Y-BOCS）and Treatment Emergent Symptom Scale （TESS）,respectively. Results The cure rate was 15.1%, 28.1% and 29.4% in group A, B and C, respectively. The total effective rate was 65.4%, 68.7% and 64.7% in group A, B and C, respectively. Compared with group A, both cure rate and total effective rate significantly increased in group B and C （P〈0.05）. There were no significant differences in the incidence of adverse reactions among the three groups（P〉0.05）. Conclusion Low-dose aripiprazole exerts a significant synergistic effect and does not cause serious adverse reactions in the treatment of obsessive compulsive disorder.
出处
《实用临床医学（江西）》
CAS
2014年第2期13-14,17,共3页
Practical Clinical Medicine
关键词
阿立派唑
增效剂
盐酸帕罗西汀
强迫症
aripiprazole
synergist
paroxetine hydrochloride
obsessive compulsive disorder
